Study to evaluate the efficacy of 5 weeks and 6 weeks intervals tocilizumab infusion in active rheumatoid arthritis patients.

Trial Profile

Study to evaluate the efficacy of 5 weeks and 6 weeks intervals tocilizumab infusion in active rheumatoid arthritis patients.

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Nov 2015

At a glance

  • Drugs Tocilizumab (Primary) ; Methotrexate; Prednisolone
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms SIWETO
  • Most Recent Events

    • 29 Jul 2015 New trial record
    • 13 Jun 2015 Results presented at the 16th Annual Congress of the European League Against Rheumatism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top